Months after emerging from stealth, Nuvalent follows up with $135M Series B — backed by some active players on the biotech IPO scene

Amber Tong

When Matt Shair unveiled a $50 million Series A for his latest targeted therapy startup earlier this year, the Harvard professor was pleased with how …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months after emerging from stealth, Nuvalent follows up with $135M Series B — backed by some active players on the biotech IPO scene

Amber Tong

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Acadia snaps up an essential tremor drug after field's summer setbacks

Months af­ter emerg­ing from stealth, Nu­va­lent fol­lows up with $135M Se­ries B — backed by some ac­tive play­ers on the biotech IPO scene

Amber Tong

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Months after emerging from stealth, Nuvalent follows up with $135M Series B — backed by some active players on the biotech IPO scene

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Acadia snaps up an essential tremor drug after field's summer setbacks